Skip to main content

Advertisement

Table 5 Summary of data published from phase III-IV trials on eribulin mesylate in metastatic breast cancer

From: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

Study (years) Phase Treatment Patients (n) OS (months) PFS (months) DOR (months) OR (%) Ref.
Cortes et al. (2011) [13] III Eribulin mesylate vs TPC 508 vs 254 13.1 3.7 3.9 13 [6]
Kaufman et al. (2012) [10] III Eribulin mesylate vs Capecitabine 554 vs 548 15.9 4.2 4.1 11 [10]
Ramaswami et al. (2014) [16] IV Eribulin mesylate 25 5.89 4.08 - 16 [16]
Poletti et al. (2014) [17] IV Eribulin mesylate 27 8 - 2.5 9 [17]
Gamucci et al. (2014) [18] IV Eribulin mesylate 133 14.3 4.4 5.2 21.1 [18]
Rasmussen et al. (2014) [19] IV Eribulin mesylate 44 - - - 12.5 [19]
Present study IV Eribulin mesylate 258 11.2 3.8 4.4 26  
  1. DOR Duration Of Response, OR Objective Response, OS Overall Survival, PFS Progression-free survival, TPC Treatment of physician’s choice